Pharmaceutical Contract Manufacturing & Research Services Market

The Pharmaceutical Contract Manufacturing & Research Services Market is projected to reach USD 237.20 Billion in 2026. It is expected to continue growing at a CAGR of 10.92%, reaching USD 444.03 Billion by 2032.

Pharmaceutical contract manufacturing and research services are moving from tactical outsourcing to a strategic operating model for drug developers, biotechnology companies, and specialty pharmaceutical firms. Contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) support discovery, preclinical research, clinical trial execution, regulatory submissions, API manufacturing, biologics production, sterile fill-finish, packaging, and post-approval lifecycle management.

Demand is anchored in measurable industry realities: the U.S. FDA Center for Drug Evaluation and Research approved 55 novel drugs in 2023 and 50 in 2024, while biologics, orphan drugs, oncology therapies, and complex modalities continue to increase development and manufacturing intensity. Sponsors are using external partners to access GMP capacity, scientific expertise, digital trial infrastructure, and global regulatory knowledge without carrying the full fixed-cost burden of in-house assets.

Transformative Shifts in the Pharmaceutical Outsourcing Landscape

The outsourcing landscape is being reshaped by biologics, high-potency APIs, antibody-drug conjugates, mRNA platforms, cell and gene therapies, and sterile injectables. These categories require specialized containment, aseptic processing, analytical characterization, cold-chain logistics, and validated quality systems, increasing the strategic value of CDMO and CRO partnerships.

At the same time, sponsors are rebalancing supply chains after pandemic-era disruptions, raw material constraints, and geopolitical trade risks. Nearshoring, dual sourcing, and regional redundancy are becoming standard procurement priorities. Regulatory expectations are also rising through ICH quality guidelines, FDA quality management maturity initiatives, EU GMP requirements, and data integrity enforcement, making proven compliance performance a decisive differentiator for pharmaceutical outsourcing partners.

Cumulative Impact of Artificial Intelligence on CDMO and CRO Operations

Artificial intelligence is becoming a cumulative productivity layer across pharmaceutical contract research and manufacturing. In drug discovery and preclinical research, AI-enabled modeling supports target identification, molecule screening, toxicology prediction, and protocol design. In clinical development, machine learning helps identify patient cohorts, optimize site selection, monitor trial risk, and improve decentralized trial operations.

In manufacturing, AI supports process analytical technology, predictive maintenance, deviation detection, batch-release acceleration, and yield improvement. The greatest impact is expected where AI is deployed within validated GxP frameworks, supported by auditable data lineage, cybersecurity controls, and human scientific oversight. For CDMOs and CROs, AI capability is becoming a commercial advantage rather than a back-office experiment.

Key Regional Insights Across Global Pharmaceutical Outsourcing

Asia-Pacific is a major hub for pharmaceutical contract manufacturing and research services, supported by large patient populations, competitive operating costs, expanding biologics investment, and mature capabilities in China, India, Japan, South Korea, Australia, and ASEAN markets. North America remains a premium innovation and outsourcing center, led by the United States and Canada, where venture-backed biotechnology, FDA-regulated manufacturing, and advanced clinical trial networks support high-value demand.

Europe maintains strength in quality-driven CDMO services, advanced therapies, and regulated clinical research, supported by EMA oversight and deep expertise in Germany, France, Italy, Spain, and the United Kingdom. Latin America, led by Brazil and Mexico, is gaining importance for clinical trial recruitment, regional packaging, and access to treatment-naive patient populations. The Middle East is investing in pharmaceutical localization and health security, while Africa offers long-term potential as regulatory harmonization, vaccine manufacturing investment, and clinical research infrastructure improve.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN is strengthening its role in contract research, packaging, generics manufacturing, and regional supply chain diversification as Singapore, Malaysia, Thailand, Vietnam, Indonesia, and the Philippines expand healthcare investment and regulatory cooperation. The GCC is prioritizing pharmaceutical localization, biologics access, and sovereign medicine security through national industrial strategies, public procurement reforms, and investments in local manufacturing capacity.

The European Union remains a regulatory benchmark for GMP, pharmacovigilance, and clinical research standards, making EU-based CDMOs and CROs attractive for complex programs. BRICS economies are central to API supply, generics scale, patient recruitment, and domestic innovation. G7 countries dominate high-value R&D, advanced therapy commercialization, and regulatory science, while NATO-aligned markets increasingly view pharmaceutical supply resilience, essential medicines availability, and critical input security as strategic priorities.

Key Country Insights for Pharmaceutical CDMO and CRO Strategy

The United States is an innovation-led outsourcing market with strong demand for biologics, sterile injectables, clinical trials, and advanced therapies supported by FDA regulatory pathways and a deep biotechnology ecosystem. Canada offers research depth, established academic networks, and a favorable clinical development environment, while Mexico benefits from proximity to the United States and nearshoring opportunities for packaging, logistics, and selected manufacturing activities. Brazil is Latin America's anchor for clinical research participation, regulatory modernization, and regional pharmaceutical demand.

The United Kingdom, Germany, France, Italy, and Spain remain central to European contract research and GMP manufacturing, with Germany and France particularly strong in high-quality industrial capabilities and regulated production. Russia retains domestic manufacturing needs but faces geopolitical constraints affecting international collaboration and supply chain access. China and India are major engines for API production, generics manufacturing, biologics investment, and clinical research capacity. Japan emphasizes quality, innovation, and regulated development pathways, Australia is valued for early-phase trials and R&D incentives, and South Korea is recognized for biologics CDMO scale, advanced manufacturing infrastructure, and export-oriented pharmaceutical capabilities.

Actionable Recommendations for Pharmaceutical Outsourcing Leaders

Industry leaders should build outsourcing portfolios around resilience, quality maturity, and technical fit rather than lowest unit cost. Sponsors should qualify secondary suppliers for critical APIs, sterile capacity, and single-use biologics inputs while using risk-based vendor governance aligned with ICH Q9 and ICH Q10 principles.

CDMOs and CROs should invest in differentiated capabilities, including high-potency containment, aseptic fill-finish, biologics characterization, decentralized trial platforms, real-world evidence analytics, and AI-enabled quality systems. Commercial teams should emphasize regulatory track record, inspection history, data integrity, on-time delivery, and technology transfer performance. Leaders that combine scientific specialization with flexible capacity and transparent digital collaboration will be best positioned to win long-term strategic partnerships.

Research Methodology and Data Validation Approach

This executive summary is developed using a structured secondary-research methodology focused on verified public-domain sources, regulatory guidance, industry disclosures, regulatory filings, and authoritative healthcare datasets. Core inputs include FDA, EMA, ICH, WHO, national regulatory agencies, clinical trial registries, peer-reviewed literature, public financial reports, and recognized pharmaceutical industry analyses.

The methodology emphasizes triangulation across demand indicators, regulatory developments, manufacturing capacity signals, therapeutic modality trends, and regional policy initiatives. Insights are validated for consistency, relevance, and recency, with preference given to evidence that can be corroborated through multiple reputable sources. The analysis avoids unsupported forecasts and focuses on operational, regulatory, and market dynamics that directly affect pharmaceutical contract manufacturing and research services.

Conclusion: Strategic Outlook for Pharmaceutical Outsourcing

Pharmaceutical contract manufacturing and research services are becoming essential to the global drug development value chain. As product pipelines become more complex and regulatory expectations rise, sponsors increasingly need specialized partners that can deliver scientific expertise, compliant execution, and scalable capacity across the product lifecycle.

The competitive landscape will favor CDMOs and CROs that combine quality excellence, advanced modality capabilities, digital maturity, and regional resilience. Artificial intelligence, strategic supply chain redesign, and expanding global clinical research networks will further redefine outsourcing models. Organizations that act now to strengthen partnerships, diversify supply, and modernize operations will be better positioned to accelerate development timelines and protect long-term value.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pharmaceutical Contract Manufacturing & Research Services Market, by Service Type

7.1. Introduction
7.2. Drug Substance Manufacturing
7.3. Drug Product Manufacturing
7.4. Packaging & Finishing
7.5. Development Services
7.6. Clinical Trial Services
7.7. Laboratory & Testing Services
7.7.1. Quality Control & Release Testing
7.7.2. Stability Studies
7.7.3. Bioanalytical & Microbiology Testing

8. Pharmaceutical Contract Manufacturing & Research Services Market, by Molecule Type

8.1. Introduction
8.2. Small Molecules
8.3. Biologics
8.4. Advanced Therapies

9. Pharmaceutical Contract Manufacturing & Research Services Market, by Dosage Form

9.1. Introduction
9.2. Oral Solid
9.3. Oral Liquid
9.4. Inhalation & Nasal
9.5. Ophthalmic

10. Pharmaceutical Contract Manufacturing & Research Services Market, by Application

10.1. Introduction
10.2. Oncology
10.3. Cardiovascular & Metabolic
10.4. Central Nervous System
10.5. Infectious Diseases
10.6. Immunology & Inflammation
10.7. Respiratory
10.8. Gastrointestinal & Hepatology
10.9. Dermatology
10.10. Ophthalmology
10.11. Rare Diseases & Orphan

11. Pharmaceutical Contract Manufacturing & Research Services Market, by Region

11.1. Asia-Pacific
11.2. North America
11.3. Latin America
11.4. Europe
11.5. Middle East
11.6. Africa

12. Pharmaceutical Contract Manufacturing & Research Services Market, by Group

12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO

13. Pharmaceutical Contract Manufacturing & Research Services Market, by Country

13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea

14. Competitive Landscape

14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025

15. Company Profiles

15.1. AbbVie Inc
15.2. Almac Group
15.3. Amanta Healthcare Ltd.
15.4. Aragen Life Sciences Ltd.
15.5. Automatic Liquid Packaging Solutions LLC
15.6. Baxter Pharmaceutical Solutions LLC
15.7. Boehringer Ingelheim International GmbH
15.8. Cambrex Corporation
15.9. Catalent, Inc
15.10. Curida AS
15.11. Dalton Pharma Services
15.12. Evonik Industries AG
15.13. Famar Group
15.14. Horizon Pharmaceuticals, Inc
15.15. Laboratorios SALVAT, S.A
15.16. Lonza Group Ltd.
15.17. Nephron Pharmaceuticals Corporation
15.18. Pfizer, Inc.
15.19. Recipharm AB
15.20. Rommelag SE & Co. KG
15.21. Rusoma Laboratories Private Limited
15.22. Silgan Unicep
15.23. Unither Pharmaceuticals SAS
15.24. UPM Pharmaceuticals, Inc.
15.25. Woodstock Sterile Solutions

List of Figures

FIGURE 1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

List of Tables

TABLE 1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL DRUG SUBSTANCE MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL DRUG SUBSTANCE MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL DRUG SUBSTANCE MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL DRUG PRODUCT MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL DRUG PRODUCT MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL DRUG PRODUCT MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL PACKAGING & FINISHING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL PACKAGING & FINISHING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL PACKAGING & FINISHING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL CLINICAL TRIAL SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL CLINICAL TRIAL SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL CLINICAL TRIAL SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL LABORATORY & TESTING SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL LABORATORY & TESTING SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL LABORATORY & TESTING SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL QUALITY CONTROL & RELEASE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL QUALITY CONTROL & RELEASE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL QUALITY CONTROL & RELEASE TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL STABILITY STUDIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL STABILITY STUDIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL STABILITY STUDIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL BIOANALYTICAL & MICROBIOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL BIOANALYTICAL & MICROBIOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL BIOANALYTICAL & MICROBIOLOGY TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL ADVANCED THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ADVANCED THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ADVANCED THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ORAL SOLID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ORAL SOLID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ORAL SOLID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ORAL LIQUID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ORAL LIQUID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ORAL LIQUID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL INHALATION & NASAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL INHALATION & NASAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL INHALATION & NASAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL OPHTHALMIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL OPHTHALMIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL OPHTHALMIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL CARDIOVASCULAR & METABOLIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL CARDIOVASCULAR & METABOLIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL CARDIOVASCULAR & METABOLIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL IMMUNOLOGY & INFLAMMATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL IMMUNOLOGY & INFLAMMATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL IMMUNOLOGY & INFLAMMATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL RESPIRATORY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL RESPIRATORY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL RESPIRATORY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL GASTROINTESTINAL & HEPATOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL GASTROINTESTINAL & HEPATOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL GASTROINTESTINAL & HEPATOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL DERMATOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL DERMATOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL DERMATOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL RARE DISEASES & ORPHAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL RARE DISEASES & ORPHAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL RARE DISEASES & ORPHAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 92. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 94. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 96. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 97. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 98. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 100. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 101. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 102. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 103. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 104. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 106. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 107. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 108. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 109. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 110. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 112. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 113. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 114. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 115. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 116. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 118. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 119. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 120. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 121. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 125. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 126. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 127. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 128. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 129. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 130. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 131. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 132. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 133. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 134. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 141. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 143. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 144. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 145. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 146. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 147. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 148. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 149. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 150. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 151. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 152. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 153. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 154. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 155. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 156. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 157. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 158. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 160. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 161. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 162. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 163. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 164. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 165. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 166. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 167. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 168. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 169. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 170. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 171. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 172. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 173. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 174. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 175. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 176. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 177. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 178. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 179. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 180. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 181. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 182. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 183. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 184. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 185. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 186. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 187. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 188. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 189. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 190. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 191. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 192. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 193. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 194. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 195. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 196. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 197. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 198. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 199. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 200. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 201. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 202. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 203. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 204. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 205. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 206. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 207. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 208. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 209. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 210. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 211. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 212. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 213. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 214. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 215. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 216. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 217. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 218. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 219. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 220. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 221. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 222. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 223. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 224. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 225. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 226. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 227. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 228. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 229. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 230. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 231. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 232. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 233. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 234. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 235. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 236. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 237. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 238. AUSTRALIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 239. AUSTRALIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 240. AUSTRALIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 241. AUSTRALIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 242. AUSTRALIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 243. AUSTRALIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 244. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 245. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 246. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2017-2032 (USD MILLION)
TABLE 247. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 248. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 249. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 250. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SHARE, BY KEY PLAYER, 2025
TABLE 251. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

AbbVie Inc
Almac Group
Amanta Healthcare Ltd.
Aragen Life Sciences Ltd.
Automatic Liquid Packaging Solutions LLC
Baxter Pharmaceutical Solutions LLC
Boehringer Ingelheim International GmbH
Cambrex Corporation
Catalent, Inc
Curida AS
Dalton Pharma Services
Evonik Industries AG
Famar Group
Horizon Pharmaceuticals, Inc
Laboratorios SALVAT, S.A
Lonza Group Ltd.
Nephron Pharmaceuticals Corporation
Pfizer, Inc.
Recipharm AB
Rommelag SE & Co. KG
Rusoma Laboratories Private Limited
Silgan Unicep
Unither Pharmaceuticals SAS
UPM Pharmaceuticals, Inc.
Woodstock Sterile Solutions

Table Information

Report Attribute	Details
No. of Pages	190
Published	August 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 237.2 Billion
Forecasted Market Value ( USD ) by 2032	$ 444.03 Billion
Compound Annual Growth Rate	10.9%
Regions Covered	Global
No. of Companies Mentioned	25

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3147EUR$3,545USD£2,692GBP €3497EUR$3,939USD£2,991GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4761EUR$5,363USD£4,072GBP €5290EUR$5,959USD£4,525GBP

Pharmaceutical Contract Manufacturing & Research Services Market - Global Forecast 2026-2032

Transformative Shifts in the Pharmaceutical Outsourcing Landscape

Cumulative Impact of Artificial Intelligence on CDMO and CRO Operations

Key Regional Insights Across Global Pharmaceutical Outsourcing

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

Key Country Insights for Pharmaceutical CDMO and CRO Strategy

Actionable Recommendations for Pharmaceutical Outsourcing Leaders

Research Methodology and Data Validation Approach

Conclusion: Strategic Outlook for Pharmaceutical Outsourcing

Table of Contents

Companies Mentioned

Table Information

Transformative Shifts in the Pharmaceutical Outsourcing Landscape

Cumulative Impact of Artificial Intelligence on CDMO and CRO Operations

Key Regional Insights Across Global Pharmaceutical Outsourcing

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

Key Country Insights for Pharmaceutical CDMO and CRO Strategy

Actionable Recommendations for Pharmaceutical Outsourcing Leaders

Research Methodology and Data Validation Approach

Conclusion: Strategic Outlook for Pharmaceutical Outsourcing

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Pharmaceutical Contract Manufacturing Market - Global Forecast 2026-2032

Oral Solid Dosage Contract Manufacturing Market - Global Forecast 2026-2032

High Potency API Contract Manufacturing - Global Strategic Business Report

Generic Pharmaceuticals Contract Manufacturing - Global Strategic Business Report

Oral Solid Dosage Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)